Walleye Trading’s Traws Pharma TRAW Stock Holding History

Walleye Trading’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,090	Closed	-$104K	–	5987
2021 Q3	$104K	Buy	+1,090	New	+$140K	﹤0.01%	4345

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Walleye Trading's TRAW Position: Q4 2021 in Review

Walleye Trading sold out of Traws Pharma (TRAW) in Q4 2021, closing a stake of 1,090 shares — an estimated $104K sold.

Walleye Trading first reported a position in TRAW in Q3 2021 and held it in 1 quarter. The position peaked at $104K in Q3 2021. 34 funds tracked by Wall St. Rank hold TRAW as of Q4 2021.

Walleye Trading reported no remaining Traws Pharma position as of Q4 2021 after selling out during the quarter.
Walleye Trading sold 1,090 Traws Pharma shares in Q4 2021, an estimated $104K.
Walleye Trading first reported a position in Traws Pharma in Q3 2021 and held it in 1 quarter.
Walleye Trading's Traws Pharma position peaked at $104K in Q3 2021.
34 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.